Reneuron Share Discussion Threads

[small crow] 09/6/2021 13:19

Agree - topped up. In for the medium to long-term so this is an opportunity. It will soon regain former upward trajectory to turn these 95p purchases into 150p IMO

[bantam175] 09/6/2021 13:11

Fill yer boots. Won't be down here long.

All imho dyor etc etc

[babbler] 09/6/2021 13:03

Or they find the source of the infection fairly quickly and move on.

[whatno] 09/6/2021 13:02

The implications of the delay are that they will miss the conference season this year to announce clinical data. It will also mean that they won't have 12 months data until the end of 2022. All this pushes back a potential phase 3 pivotal trial to 2023/24 with the possibility of market approval in 2025/26.

[rrb] 09/6/2021 12:49

Ridiculous overreaction. Bacterial infection is not down to the therapy. Infection risk is always present in such procedures. Not ideal but not worthy of a 25% pullback!

[stutes] 09/6/2021 12:40

Today's news hrpc trial infection is another piece of misfortune for Rene.

I think it's time for Rene to sell itself

[whatno] 09/6/2021 12:37

Let's hope there's no lasting damage. I don't believe RENE has permission from the regulators for redosing so this patient can't have a repeat.

[small crow] 09/6/2021 12:35

Massive overreaction on a generally down-day for everything, I suspect someone wants to get in cheap and has instructed accordingly - large (huge?) buys expected to show up over next few days IMO. This random unfortunate event has been a gift to them.

[bradders51] 09/6/2021 12:20

The trials have been going on for quite some time yes?

This is the first problem like this as far as I am aware.

There will be many likely causes to an infection in any surgery. Let's hope they can pin down exactly what caused it.
It sounds like the patient (poor sod - best wishes to him/her) seems to be responding well. It will be interesting to see what happens to their eyesight once the infection is dealt with.

[whatno] 09/6/2021 12:16

It's very unfortunate. I guess they need to know whether the batch was contaminated or whether the infection was introduced during the procedure itself. There's also a question of what damage the infection may have done to the transplanted cells of the unfortunate patient being treated.

[martinfrench] 09/6/2021 12:06

starting to lose my patience with this lot, not only ridiculous amount of time to get to mkt but stuff like this.

yes i know it happens but they still remind me of bunch of people doing a science project with our money with no commercial outlook at all

[goyathlay] 09/6/2021 12:04

Not exactly ideal!

""Released 11:55:07 09 June 2021

RNS Number : 3482B
ReNeuron Group plc
09 June 2021

ReNeuron Group plc
("ReNeuron" or the "Company")



Update for hRPC therapy candidate study



ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, provides an update on the Company's Phase 2a clinical evaluations for the treatment of retinitis pigmentosa ('RP'), an inherited, degenerative eye disease.



Further to the update on 15 January 2021, the Company has activated sites in Spain and the UK, to expand the Phase 2a extension study outside the US, thus representing a total of four actively enrolling sites worldwide. The most recently enrolled subject was treated last week, undergoing a successful surgical procedure to implant the hRPC drug product. Five days following treatment, the subject presented with a presumed bacterial intraocular infection in the treated eye which impacted their vision, and was treated initially with an appropriate regimen of antibiotics, to which they responded with clinical improvement. Systemic anti-inflammatory therapy was subsequently added, and the subject continues to improve on this regimen.



The origin of the presumed infection is not yet clear. As a precaution, dosing of further subjects in the study has been temporarily suspended while an investigation into the cause of the event continues. This is likely to lead to a delay to the study, and the Company now expects three-month data from the extension segment of the Phase 2a study to be available in Q4, rather than Q3, of this year.



The Company will provide a further update in due course.""

[whatno] 08/6/2021 14:30

The clinicaltrials.gov website is still showing Oxford eye hospital as "not yet recruiting". I can only assume this is due to the huge backlog of NHS work that needs to be cleared before staff can work on research projects. Unless the situation improves soon, RENE will need to make some hard choices regarding Professor Maclaren's involvement unless they opt for a delay until next year.

[bg23] 08/6/2021 13:34

Thanks. Interesting.

I know the company needs to tell a bullish story, but looking at valuations, capabilities and 'Done deals', its very easy to get into the mindset of Rene being valued at a fraction of its potential worth - even if only the hRPC proves partial efficacy.

I'd love a crystal ball!

[bradders51] 07/6/2021 17:45

Ref: IPSC's

With thanks to PhilBanks on t'other site:


Cell & Gene Meeting on the Med – CEO Investor Presentation. . . .


H.C. Wainwright Global Life Sciences Conference. . . .


Both are presented by Olav, and the content is pretty similar. They also both finish with interesting comments regarding the iPSC platform, if you want to skip to the final 30s or so.

1st video:

". . . and there's another programme that I haven't talked about, which is the iPSCs where we also have huge potential over the next few months. . . "

2nd video:

". . . I didn't go into the iPSCs any further, please go to our website to look at that. It is an earlier stage programme than the exosomes, but the potential is enormous . . ."

[bg23] 07/6/2021 13:54

I seem to remember there are several data points coming up in the next month or so?

I also found the below on the website. not sure I had seen any references to this side of the gene therapy platforms before. looks and sounds exciting

hxxp://www.reneuron.com/products/induced-pluripotent-stem-cell-ipsc-platform/

[brucie5] 04/6/2021 10:08

Bounce overdue, perhaps; but it needs to rise over 1.50 before we can get remotely excited. Beyond that, the gap up looks towards £2 and £2.50. Strong hold afaic.

[dickbush] 04/6/2021 09:50

Chart looking good. Let's hope the fundamentals give a reason for optimism.

[tole] 28/5/2021 13:56

Interesting trade of 255k @ 126p paid gone through. A penny premium for a nice sum.

[stutes] 20/5/2021 11:38

Has Dr Corteling left Rene, as I thought he was Chief Scientific Officer?

[pdt] 16/5/2021 15:46

Biogen reveals gene therapy trial failure as investors remain laser-focused on aducanumab drama



A gene therapy approach to RP has failed.

That therapy came out of a $877 million deal for British biotech Nightstar Therapeutics.

We know that Reneuron's RP 12 month results look good, makes the company's market cap of £70m look a bit of a bargain ?

[whatno] 13/5/2021 15:27

The problem is that Oxford eye hospital is still not recruiting according to clinicaltrials.gov. The big hope was that by adding Oxford's Professor Maclaren Reneuron would boost the trial's profile.